November 7, 2017

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Re: Combined Warning letter issued by USFDA for Company's Goa and Indore (Pithampur Unit II) sites.

This is to bring to your notice that the Company received a warning letter issued by the USFDA on November 6, 2017, for our formulation manufacturing facilities at Goa and Indore (Pithampur Unit II).

We had earlier received three Form 483 observations in Goa on April 7, 2017 and six Form 483 observations in Pithampur (Unit II) on May 19, 2017. We had responded to all the observations.

We are deeply disappointed to have received this outcome. While there will be no disruption of existing product supplies from either of these locations, there will likely be a delay of new product approvals from these two facilities.

We uphold quality and compliance issues with utmost seriousness and remain fully committed to be compliant with cGMP quality standards across all our facilities. We plan to address the concerns raised by the USFDA expeditiously and will work with the USFDA to resolve these issues at the earliest.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**

R. V. SATAM
COMPANY SECRETARY

LUPIN LIMITED
MUMBAI INDIA